Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Jonsson Comprehensive Cancer Center
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07619313CT.gov AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Cholangiocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ligritinib (this asset) | Jonsson Comprehensive Cancer Center | P1 | CC · 43 |
| Fluorouracilum | Jonsson Comprehensive Cancer Center | P3 | BB |
| Irinotecan | Jonsson Comprehensive Cancer Center | P3 | B |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P3 | B |
| Etomidate | Cheju Halla General Hospital | P4 | B |
| Docetaxel | Merck Sharp & Dohme LLC | P2 | B |
| Meperidine | Cheju Halla General Hospital | P4 | B |
| Trametinib | National Cancer Institute (NCI) | P2 | B |
| Nivolumab | Instituto do Cancer do Estado de São Paulo | P2 | B |
+42 more in the Cholangiocarcinoma cohort
Other indications for Ligritinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Pancreatic Ductal Adenocarcinoma | — | P1 | CC · 43 |
| Malignant Pancreatic Neoplasm | — | P1 | CC · 43 |
| Pancreatic Adenocarcinoma | — | P1 | CC · 41 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ligritinib in Cholangiocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ligritinib-cholangiocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →